(Q24242960)

30 October 2023

Robert Vander Stichele

series ordinal

2

author given names

R

author last names

Vander Stichele

1 reference

30 October 2023

Philippe Lehert

series ordinal

3

author given names

P

author last names

Lehert

1 reference

30 October 2023

Luc Van Bortel

series ordinal

4

author given names

L

author last names

Van Bortel

1 reference

Cochrane Database of Systematic Reviews

30 October 2023

publication date

23 April 2008

0 references

published in

0 references

cites work

Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Lipid-lowering for peripheral arterial disease of the lower limb

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Management of peripheral arterial disease in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Intermittent claudication and rest pain: Physiologic concepts and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

The prevalence of peripheral arterial disease in a defined population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Buflomedil for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Oral vasoactive medication in intermittent claudication: utile or futile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Naftidrofuryl: a review of its use in the treatment of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Meta-analysis of continuous outcome data from individual patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Vitamin E for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Exercise for intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Pharmacological management of intermittent claudication: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Peripheral arterial disease: identification and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Prostanoids for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Cilostazol for peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Omega-3 fatty acids for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

A multilevel model framework for meta-analysis of clinical trials with binary outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

7 January 2021

Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

7 January 2021

Naftidrofuryl for intermittent claudication: a double-blind controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

7 January 2021

Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

7 January 2021

Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

7 January 2021

Effects of naftidrofuryl in patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

7 January 2021

[Epidemiology and prognosis of peripheral obliterative arteriopathy].

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001368.PUB3

7 January 2021

10.1002/14651858.CD001368.PUB3

Identifiers

DOI

0 references

Fatcat ID

release_ixxpsbbacvejvkqhpnutllgf3y

0 references